Literature DB >> 35623709

Nanoluciferase-based complementation assay for systematic profiling of GPCR-GRK interactions.

Christie B Palmer1, Giulia D'Uonnolo1, Rafael Luís2, Max Meyrath3, Tomasz Uchański3, Andy Chevigné4, Martyna Szpakowska5.   

Abstract

G protein-coupled receptor kinases (GRKs) are a family of seven soluble receptor-modifying enzymes which are essential regulators of GPCR activity. Following agonist-induced receptor activation and G protein dissociation, GRKs prime the receptor for desensitization through phosphorylation of its C terminus, which subsequently allows arrestins to bind and initiate the receptor internalization process. While GRKs constitute key GPCR-interacting proteins, to date, no method has been put forward to readily and systematically determine the preference of a specific GPCR towards the seven different GRKs (GRK1-7). This chapter describes a simple and standardized approach for systematic profiling of GRK1-7-GPCR interactions relying on the complementation of the split Nanoluciferase (NanoBiT). When applied to a set of GPCRs (MOR, 5-HT1A, B2AR, CXCR3, AVPR2, CGRPR), including two intrinsically β-arrestin-biased receptors (ACKR2 and ACKR3), this methodology yields highly reproducible results highlighting different GRK recruitment profiles. Using this assay, further characterization of MOR, a crucial target in the development of analgesics, reveals not only its GRK fingerprint but also related kinetics and activity of various ligands for a single GRK.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACKR3; Arrestin; B2AR; GRK2; GRK3; GRK5; GRK6; Kinase; MOR; NanoBiT; opioids

Mesh:

Substances:

Year:  2022        PMID: 35623709     DOI: 10.1016/bs.mcb.2022.04.001

Source DB:  PubMed          Journal:  Methods Cell Biol        ISSN: 0091-679X            Impact factor:   1.441


  1 in total

1.  Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples.

Authors:  Max Meyrath; Martyna Szpakowska; Jean-Marc Plesseria; Olivia Domingues; Jérémie Langlet; Bernard Weber; Rejko Krüger; Markus Ollert; Andy Chevigné
Journal:  Methods Enzymol       Date:  2022-09-09       Impact factor: 1.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.